價格 | ¥297 | ¥496 | ¥738 |
包裝 | 2mg | 5mg | 10mg |
最小起訂量 | 1mg |
發(fā)貨地 | 上海 |
更新日期 | 2024-12-12 |
中文名稱:化合物 PD166866 | 英文名稱:PD-166866 |
CAS:192705-79-6 | 品牌: TargetMol |
產(chǎn)地: 美國 | 保存條件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
純度規(guī)格: 99.98% | 產(chǎn)品類別: 抑制劑 |
貨號: T3492 |
名稱 | PD-166866 |
描述 | PD-166866 is a selective FGFR tyrosine kinase inhibitor. |
細胞實驗 | HeLa cells are treated with PD166866 for 24 hours, the growth medium is removed, the cells are washed with PBS and fixed for 1 hour at 25°C adding a freshly made paraformaldheyde solution (4% in PBS). Samples are washed again with PBS and the endogenous oxidases were blocked for 2 minutes in the dark. Further washes with PBS followed and blocking the unspecific sites is done for 1 hour at 25℃. PARP is evidenced by immunolocalization utilizing a polyclonal antibody, directed against the N-terminal proteolytic fragment. Immuno-reaction is revealed by a secondary anti-rabbit antibody after incubation for 16 hours at 4°C. After exhaustive washing with PBS the samples are incubated for 30 minutes in solution ABC. Eventually, DAB (3,3'-Diaminobenzidine) is added and the samples are incubated for 10 minutes in the dark. The samples are washed again the plates are sealed and ready for microscopic observation.(Only for Reference) |
體外活性 | PD166866顯著導(dǎo)致線粒體缺陷和氧化應(yīng)激[1]。PD 166866以52.4 ± 0.1 nM的IC50值抑制人源全長FGFR-1酪氨酸激酶,但對c-Src、血小板衍生生長因子受體β、表皮生長因子受體或胰島素受體酪氨酸激酶、絲裂原活化蛋白激酶、蛋白激酶C和CDK4在高達50 μM的濃度下無效。PD 166866強效抑制在NIH 3T3細胞中表達內(nèi)源性FGFR-1和在L6細胞過表達人FGFR-1酪氨酸激酶的基礎(chǔ)成纖維生長因子(bFGF)介導(dǎo)的受體自磷酸化。PD 166866不抑制在血管平滑肌、A431或NIHIR細胞中由血小板衍生生長因子、表皮生長因子或胰島素刺激的受體自磷酸化,進一步支持其對FGFR-1的特異性。此外,PD 166866是一種強效的抑制人胎盤培養(yǎng)動脈碎片中的微血管生長(血管生成)的抑制劑。在L6細胞中,被PD 166866抑制的磷酸化44-和42-kDa MAPK亞型的IC50值分別為4.3和7.9 nM[2]。PD166866通過抑制Akt/mTOR信號路徑誘導(dǎo)自噬[3]。 |
存儲條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
溶解度 | DMSO : 12 mg/mL (30.3 mM) H2O : < 1 mg/mL (insoluble or slightly soluble) Ethanol : 3 mg/mL (7.57 mM) |
關(guān)鍵字 | Inhibitor | Autophagy | FGFR | PD 166866 | inhibit | PD-166866 | Fibroblast growth factor receptor |
相關(guān)產(chǎn)品 | Guanidine hydrochloride | Naringin | Valproic Acid | Taurine | Gefitinib | Aceglutamide | Hydroxychloroquine | Ferulic Acid | Curcumin | Stavudine | Paeonol | Sodium 4-phenylbutyrate |
相關(guān)庫 | 抑制劑庫 | 抗癌活性化合物庫 | 經(jīng)典已知活性庫 | 已知活性化合物庫 | 激酶抑制劑庫 | 抗衰老化合物庫 | 高選擇性抑制劑庫 | 膜蛋白靶向化合物庫 | 酪氨酸激酶分子庫 | 抗前列腺癌化合物庫 |
成立日期 | 2013-04-18 (12年) | 注冊資本 | 566.265100萬人民幣 |
員工人數(shù) | 100-500人 | 年營業(yè)額 | ¥ 1億以上 |
主營行業(yè) | 天然產(chǎn)物,生化試劑,分子生物學(xué),分子砌塊,生物技術(shù)服務(wù) | 經(jīng)營模式 | 貿(mào)易,工廠,試劑,定制,服務(wù) |
產(chǎn)品名稱 | 價格 | 公司名稱 | 報價日期 | |
---|---|---|---|---|
詢價 |
VIP3年
|
陜西締都新材料有限公司
|
2024-12-18 | |
詢價 |
VIP1年
|
青島愷潤生物醫(yī)藥科技有限公司
|
2024-11-02 | |
¥198 |
VIP12年
|
上海陶術(shù)生物科技有限公司
|
2024-12-02 | |
詢價 |
VIP6年
|
上海澤葉生物科技有限公司
|
2024-12-26 | |
¥1750.90 |
VIP1年
|
上海阿拉丁生化科技股份有限公司
|
2024-11-29 |